CLINICAL EFFICACY AND SAFETY OF NICORANDIL: AN ADDITIONAL OPPORTUNITY TO IMPROVE THE TREATMENT OF PATIENTS WITH STABLE ANGINA

Download full text PDF
Issue: 
12
Year: 
2016

E. Ryabikhin, Candidate of Medical Sciences; M. Mozheiko, MD; Yu. Krasilnikova Regional Clinical Hospital for War Veterans, International Healthy Longevity Center, Yaroslavl

Adding nicorandil to standard therapy for coronary heart disease allows for not only improving the quality of life of patients, but also for positively affecting the elasticity of the great vessels and the morphofunctional parameters of the heart.
Keywords: 
cardiology
vessel stiffness
coronary heart disease
quality of life
nicorandil

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force of the European Society of Cardiology // Eur. Heart J. – 2013; 34 (38): 2949–3003.
  2. Klinicheskie rekomendatsii. Diagnostika i lechenie hronicheskoj ishemicheskoj bolezni serdtsa // Kardiol. vestn. – 2015; 3: 3–33.
  3. Airaksinen K., Huikuri H. Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty // J. Am. Coll. Cardiol. – 1997; 29 (5): 1035.
  4. Yang J., Zhang J., Cui W. et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention // Anadolu Kardiyol. Derg. – 2015; 15 (2): 125–31.
  5. Sakamoto T., Kaikita K., Miyamoto S. et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease // Circ. J. – 2004; 68: 232–56.
  6. Izumiya Y., Kojima S., Araki S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. – 2011; 214 (2): 415–21.
  7. Markham A., Plosker G., Goa K. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardio-protective effects // Drugs. – 2000; 60: 955–74.
  8. Sekiya M., Sato M., Funada J. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. – 2005; 46 (1): 63–7.
  9. Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction // J. Nucl. Med. – 2007; 48 (10): 1676–82.
  10. Kasama S., Toyama T., Hatori T. et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy // Am. Heart J. – 2005; 150 (3): 477.e1–477.e8.
  11. The IONA Study Grup.Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial // Lancet. – 2002; 359 (9314): 1269–75.
  12. Horinaka S., Yabe A., Yagi H. et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study // Circ. J. – 2010; 74 (3): 503–9.
  13. Ishihara M., Sato H., Tateishi H. et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis // J. Am. Coll. Cardiol. – 1997; 30 (4): 970–5.
  14. Rezkalla S., Kloner R. Preconditioning in humans // Heart Fail. Rev. – 2007; 12 (3–4): 201–6.
  15. Vatutin N.T., Kalinkina N.V., Kolesnikov V.S. i dr. Fenomen prekonditsionirovanija // Serdtse. – 2013; 12 (4): 199–206.
  16. Bulahova E.Ju., Korennova O.Ju., Kondrasheva M.N. i dr. Klinicheskie preimuschestva terapii nikorandilom v sravnenii s izosorbid-5-mononitratom u bol'nyh IBS // Serdtse. – 2013; 12 (2): 83–7.
  17. Rezvanova Ju.A., Adamchik A.S. Otsenka antiishemicheskoj i kardioprotektivnoj effektivnosti nikorandila u patsientov so stabil'noj stenokardiej // Kardiologija. – 2015; 8 (55): 21–5.
  18. Sizova Zh.M., Zaharova V.L., Shamieva E.S. i dr. Vozmozhnosti nikorandila v korrektsii koronarnogo rezerva i endotelial'noj disfunktsii u bol'nyh ishemicheskoj bolezn'ju serdtsa // Serdtse. – 2013; 12 (2): 75–82.
  19. Rjabihin E.A., Mozhejko M.E., Krasil'nikova Ju.A. Effektivnost' i bezopasnost' dlitel'noj terapii nikorandilom bol'nyh stabil'noj stenokardiej // Serdtse. – 2014; 13 (3): 151–5.
  20. Rjabihin E.A., Mozhejko M.E., Krasil'nikova Ju.A. i dr. Dopolnitel'nye vozmozhnosti v lechenii ishemicheskoj bolezni serdtsa, oslozhnennoj hronicheskoj serdechnoj nedostatochnost'ju s nizkoj fraktsiej vybrosa levogo zheludochka // Serdechnaja nedostatochnost'. – 2016; 17 (1): 3–9.
  21. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization // Drugs. – 2011; 71 (9): 1105–19.
  22. Popele van N., Grobbee D., Bots M. et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study // Stroke. – 2001; 32 (2): 454–60.
  23. Iljuhin O.V., Iljuhina M.V., Tarasov D.L. i dr. Skorost' pul'sovoj volny kak marker riska serdechno-sosudistyh oslozhnenij u bol'nyh stabil'noj ishemicheskoj bolezn'ju serdtsa // Ros. kardiol. zhurn. – 2013; 5 (103): 12–7.